Twist Bioscience reported its fiscal Q3 results highlighted by strong growth momentum. ... TWST) commercializes a DNA synthesis platform that automates synthetic DNA production on a silicon chip.

Twist Bioscience share price has fallen by 50% since the beginning of 2022. Management thinks DNA data storage could be $2 billion market for the company, aided by early mover advantage and ...

Twist Bioscience Corporation (NASDAQ: ... $3.1 billion as of February 2025, the company has been attracting attention for its innovative approaches to DNA synthesis and storage.

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of Twist Express ...

SOUTH SAN FRANCISCO, Calif., August 08, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its ...

“The vast majority of DNA synthesis companies are good actors, but there are some companies that are not good actors,” Emily Leproust, the CEO of Twist Bioscience, told me.

Benzinga - by Vandana Singh, Benzinga Editor. Twist Bioscience Corp (NASDAQ:TWST) shares are trading higher after the company released first-quarter 2024 earnings and increased its FY24 revenue ...

Twist Bioscience, a synthetic biology and genomics company, announced on Nov. 14, 2023 that it has launched Express Genes, a new gene synthesis service with a quick turnaround time of five to seven ...